Wall Street gains after reports of Boeing to resume production next week; investors cheer Trump's plan to reopen economy
Boeing's shares soared 11.7 percent on plans to resume commercial aircraft production in Washington state after halting operations last month due to the coronavirus pandemic
Wall Street bounced on Friday as Boeing said it would resume production of commercial jets next week, with investors also cheering President Donald Trump’s plan to reopen the economy and on hopes of a potential drug to treat COVID-19.
The US planemaker’s shares soared 11.7 percent on plans to resume commercial aircraft production in Washington state after halting operations last month due to the coronavirus pandemic.
The S&P 500 has now regained about 30 percent from a March trough and is set for its third weekly gain in four, following a raft of global stimulus and on hopes that statewide lockdowns would be eased as the outbreak showed signs of ebbing.
However, the index is still about 19 percent away from reclaiming its all-time high and analysts have warned of a deep economic slump, as a halt in business activity puts millions of Americans out of work.
“The overall picture remains one of high uncertainty with things certainly looking up from a month ago, but the economic and public-health outlook is still far from rosy,” said Art Hogan, chief market strategist at National Securities in New York.
Late on Thursday, Trump outlined a plan to reopen US states in a staggered, three-stage process, but the plan was a set of recommendations rather than orders and left the decision largely up to state governors.
In a bright spot, big US lenders rebounded 5.7 percent after four straight days of losses on reporting several billion dollars in reserves to cover potential loan defaults. Financial stocks were the top boost to the S&P 500.
Gilead Sciences Inc surged 8.2 percent following a media report that patients with severe symptoms of the disease had responded positively to its experimental drug, remdesivir.
With no treatments or vaccines currently approved for the coronavirus, the news lifted global equity markets, but Gilead said the totality of the data from the trial needed to be analyzed and that it expected to report results from a study in severe COVID-19 patients at the end of April.
“The anecdotal evidence out of Gilead’s Chicago trials for remdesivir are just that: anecdotal, even though they are part of a Phase 3 trial,” said Peter Cecchini, managing director and chief market strategist at Cantor Fitzgerald in New York.
The risk-on sentiment pushed Wall Street’s fear gauge below 40 and sent safe-haven gold tumbling almost 2 percent.
At 10:25 AM ET, the Dow Jones Industrial Average was up 380.07 points, or 1.61 percent, at 23,917.75, the S&P 500 was up 46.40 points, or 1.66 percent, at 2,845.95. The Nasdaq Composite was up 79.87 points, or 0.94 percent, at 8,612.23.
Amazon.com Inc and streaming platform Netflix Inc retreated slightly from record highs after surging this week on higher demand for online streaming services and home delivery of goods.
The world’s top oilfield services provider Schlumberger NV rose 5.4 percent even as it swung to a loss in the first quarter on $8.5 billion in asset writedowns and cut its dividend.
Apple Inc fell 1.9 percent as Goldman Sachs downgraded its stock, expecting iPhone shipments to drop 36 percent during the third quarter due to coronavirus-related lockdowns.
The US-based Institute for Health Metrics and Evaluation (IHME) estimates that nearly 145 million people worldwide had at least one of those symptoms in 2020 and 2021
A team led by researchers at Washington State University, US, found spike proteins from the bat virus, named Khosta-2, can infect human cells and is resistant to both the antibody therapies and blood serum from people vaccinated forS-CoV-2
"During our study, we couldn't detect viral particles in the cardiac tissues of COVID-19 patients, but what we found was tissue changes associated with DNA damage and repair,"